SCHEMBL18148216

SCHEMBL18148216

O=C1COC(=O)N1C=Cc1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 10/20 0.67
AKT1 P31749 2/20 0.60
PKM P14618 2/20 0.41
HSD17B10 Q99714 1/20 0.41
PGAM1 P18669 1/20 0.39
BRAF P15056 3/20 0.38
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
CCR2 P41597 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20798601 1.00 CNKSR1 (0.67) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL15811533 1.00 CNKSR1 (0.67) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL18147993 0.88 CNKSR1 (0.70) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL15811538 0.88 CNKSR1 (0.70) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL18148011 0.85 CNKSR1 (0.64) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL15811489 0.85 CNKSR1 (0.64) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL19867308 0.82 CNKSR1 (0.65) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL18148094 0.81 CNKSR1 (0.65) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL18148081 0.81 CNKSR1 (0.65) CNKSR1AKT1PKMHSD17B10PGAM1
SCHEMBL15811542 0.81 CNKSR1 (0.65) CNKSR1AKT1PKMHSD17B10PGAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
EP-2931280-B1 METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS INC (US) 2018-02-14 EP disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885PKM 924/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885PKM 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.